Phil Rowlands Healthcare News

This is selected healthcare news for Phil Rowlands, which is filed under People. There are 19 news items for this page. A press release filter page is also available for Phil Rowlands.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
12/7/2019 Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
... treatment options for this underserved patient population is critical.” “We look forward to the opportunity to share the data from the TOURMALINE-AL1 trial,” said Phil Rowlands, Head of Oncology Clinical Research and Development, Takeda. “We are confident that sharing our findings with the community will help encourage conversations around ...
Business Wire
12/7/2019 Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
... treatment options for this underserved patient population is critical.” “We look forward to the opportunity to share the data from the TOURMALINE-AL1 trial,” said Phil Rowlands , Head of Oncology Clinical Research and Development, Takeda. “We are confident that sharing our findings with the community will help encourage conversations around ...
Financial Times
12/7/2019 Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis | Business & Finance | manchestertimes.com
... treatment options for this underserved patient population is critical.” “We look forward to the opportunity to share the data from the TOURMALINE-AL1 trial,” said Phil Rowlands, Head of Oncology Clinical Research and Development, Takeda. “We are confident that sharing our findings with the community will help encourage conversations around ...
Business Wire
11/23/2019 Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up
... At Takeda, we are committed to developing products that seek to advance the lung cancer treatment landscape and address the unmet needs of patients,” said Phil Rowlands, Head, Oncology Therapeutic Area Unit. “We are proud of the progress made thus far, including these updated results from the ALTA-1L trial ...
Business Wire
11/23/2019 Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up
... At Takeda, we are committed to developing products that seek to advance the lung cancer treatment landscape and address the unmet needs of patients,” said Phil Rowlands, Head, Oncology Therapeutic Area Unit. “We are proud of the progress made thus far, including these updated results from the ALTA-1L trial ...
Business Wire
11/16/2019 Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting
... programs at ASH, highlighting our deep oncology pipeline and our commitment to developing innovative therapies that may address unmet needs for blood cancer patients,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “In particular we look forward to sharing data from the Phase 3 clinical trial of ixazomib ...
blogspot.com
11/16/2019 Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting
... programs at ASH, highlighting our deep oncology pipeline and our commitment to developing innovative therapies that may address unmet needs for blood cancer patients,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “In particular we look forward to sharing data from the Phase 3 clinical trial of ixazomib ...
blogspot.com
11/16/2019 Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting
... programs at ASH, highlighting our deep oncology pipeline and our commitment to developing innovative therapies that may address unmet needs for blood cancer patients,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “In particular we look forward to sharing data from the Phase 3 clinical trial of ixazomib ...
blogspot.com
11/15/2019 Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st …
... programs at ASH, highlighting our deep oncology pipeline and our commitment to developing innovative therapies that may address unmet needs for blood cancer patients,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “In particular we look forward to sharing data from the Phase 3 clinical trial of ixazomib ...
aetoswire.com
11/13/2019 Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
... momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout from the TOURMALINE clinical trial program,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “We remain committed to bringing this convenient and well-tolerated treatment option to patients.” The safety ...
blogspot.com
11/13/2019 Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
... momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout from the TOURMALINE clinical trial program,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “We remain committed to bringing this convenient and well-tolerated treatment option to patients.” The safety ...
blogspot.com
11/7/2019 Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
... momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout from the TOURMALINE clinical trial program,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “We remain committed to bringing this convenient and well-tolerated treatment option to patients.” The safety ...
BioSpace
6/5/2019 Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis | Business & Finance | heraldchronicle.com
... learnings from this trial and share findings with the community in hopes of helping to improve care for patients living with this devastating disease,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “This has been one of the largest studies ever conducted in systemic light-chain AL amyloidosis ...
Business Wire
5/16/2019 Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses
... and EHA that illustrate the continued progress of our portfolio in both clinical research and real-world settings in solid tumors and blood cancers,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “These data demonstrate our continued commitment to the discovery, development and delivery of medicines for patients ...
Business Wire